Evidence map›Paper›PMID 42111346›Full record

ArticleLiver cancer2026

Characterization of Patients with Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated with Lenvatinib.

Amit Mahipal, Ann-Lii Cheng, Masatoshi Kudo, Adam Burgoyne, Aparna Kalyan, Riccardo Lencioni, Carlos Lopéz Lopéz, Bruno Daniele, Daniel H Palmer, Ari David Baron and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01761266 (A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01761266 phase3completednot on this map

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

TypeinterventionalSponsorEisai LimitedRan2013 to 2021Enrolled954ConditionsHepatocellular Carcinoma (HCC)ArmsLenvatinib, Sorafenib
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Amit MahipalDivision of Hematology/Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Ann-Lii ChengDepartment of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Adam BurgoyneDivision of Hematology-Oncology, University of California San Diego, San Diego, CA, USA.
Aparna KalyanDivision of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Riccardo LencioniDepartment of Radiology, University of Pisa, Pisa, Italy.
Carlos Lopéz LopézDepartment of Medical Oncology, Marqués de Valdecilla University Hospital, IDIVAL, UNICAN, Santander, Spain.
Bruno DanieleDepartment of Oncology and Hematology, Ospedale del Mare, Naples, Italy.
Daniel H PalmerDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Ari David BaronDivision of Hematology-Oncology, Sutter/California Pacific Medical Center, San Francisco, CA, USA.
Joong-Won ParkDepartment of Gastroenterology and Hepatology, Myongji Hospital, Goyang-Si, South Korea.
Min RenEisai Inc., Nutley, NJ, USA.
Kalgi ModyEisai Inc., Nutley, NJ, USA.
Arndt VogelDivision of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The phase 3 REFLECT study (NCT01761266) established lenvatinib's noninferiority to sorafenib for unresectable hepatocellular carcinoma (uHCC). This subanalysis examines patients treated with lenvatinib according to the depth of their tumor response and their status as an alpha-fetoprotein (AFP) responder/nonresponder. Methods: Of 478 lenvatinib-treated patients, 194 achieved an objective response by mRECIST per independent imaging review. Patients with tumor response were further categorized by their maximal tumor reduction (assessed every 8 weeks). Patients were also assessed according to their AFP response (≥20% reduction from baseline by week 8) status, including AFP responders ( Results: Median duration of response in patients with ≥75% ( Conclusions: This analysis highlights the importance of tumor reduction and AFP response as predictors of survival outcomes in lenvatinib-treated patients with uHCC. These data continue to support lenvatinib as an effective first-line treatment option.

Indexed as

Alpha-fetoproteinHepatocellular carcinomaLenvatinibLiver cancerREFLECTTumor

Identifiers

PMID42111346
PMCPMC13155761

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.